Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nilotinib induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-chronic myeloid leukemia.
Pungolino E, Rossi G, De Canal G, Trojani A, D'adda M, Perego A, Orlandi EM, Lunghi F, Turrini M, Borin L, Iurlo A, Latargia ML, Carraro MC, Spina F, Lodola M, Artale S, Anghilieri M, Spedini P, Cantoni S, Di Camillo B, Morra E, Cairoli R. Pungolino E, et al. Among authors: carraro mc. Am J Hematol. 2018 Jul;93(7):E162-E164. doi: 10.1002/ajh.25106. Epub 2018 May 17. Am J Hematol. 2018. PMID: 29633310 Free article. No abstract available.
Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment.
Trojani A, Pungolino E, Rossi G, D'Adda M, Lodola M, Camillo BD, Perego A, Turrini M, Orlandi E, Borin L, Iurlo A, Malato S, Spina F, Latargia ML, Lanza F, Artale S, Anghilieri M, Carraro MC, Canal G, Morra E, Cairoli R. Trojani A, et al. Among authors: carraro mc. Cancer Biomark. 2017 Dec 12;21(1):41-53. doi: 10.3233/CBM-170209. Cancer Biomark. 2017. PMID: 29036785
Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatment.
Trojani A, Pungolino E, Dal Molin A, Lodola M, Rossi G, D'Adda M, Perego A, Elena C, Turrini M, Borin L, Bucelli C, Malato S, Carraro MC, Spina F, Latargia ML, Artale S, Spedini P, Anghilieri M, Di Camillo B, Baruzzo G, De Canal G, Iurlo A, Morra E, Cairoli R. Trojani A, et al. Among authors: carraro mc. PLoS One. 2019 Jul 18;14(7):e0218444. doi: 10.1371/journal.pone.0218444. eCollection 2019. PLoS One. 2019. PMID: 31318870 Free PMC article. Clinical Trial.
Nilotinib-induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-Chronic Myeloid Leukemia: Final report of the PhilosoPhi34 study.
Pungolino E, D'adda M, De Canal G, Trojani A, Perego A, Elena C, Lunghi F, Turrini M, Borin L, Iurlo A, Latargia ML, Carraro MC, Spina F, Artale S, Anghilieri M, Molteni A, Caramella M, Baruzzo G, Nichelatti M, Di Camillo B, Cairoli R. Pungolino E, et al. Among authors: carraro mc. Eur J Haematol. 2021 Oct;107(4):436-448. doi: 10.1111/ejh.13680. Epub 2021 Jul 6. Eur J Haematol. 2021. PMID: 34139044 Free PMC article. Clinical Trial.
Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study.
Gemelli M, Elli EM, Elena C, Iurlo A, Intermesoli T, Maffioli M, Pungolino E, Carraro MC, D'Adda M, Lunghi F, Anghileri M, Polverelli N, Rossi M, Bacciocchi M, Bono E, Bucelli C, Passamonti F, Antolini L, Gambacorti-Passerini C. Gemelli M, et al. Among authors: carraro mc. Blood Res. 2020 Sep 30;55(3):139-145. doi: 10.5045/br.2020.2020130. Blood Res. 2020. PMID: 32792470 Free PMC article.
Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.
Maffioli M, Giorgino T, Mora B, Iurlo A, Elli E, Finazzi MC, Caramella M, Rumi E, Carraro MC, Polverelli N, D'Adda M, Malato S, Rossi M, Molteni A, Vismara A, Sissa C, Spina F, Anghilieri M, Cattaneo D, Renso R, Bellini M, Pioltelli ML, Cavalloni C, Barraco D, Accetta R, Bertù L, Della Porta MG, Passamonti F. Maffioli M, et al. Among authors: carraro mc. Blood Adv. 2019 Nov 12;3(21):3196-3200. doi: 10.1182/bloodadvances.2019000646. Blood Adv. 2019. PMID: 31698448 Free PMC article.
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis.
Maffioli M, Mora B, Ball S, Iurlo A, Elli EM, Finazzi MC, Polverelli N, Rumi E, Caramella M, Carraro MC, D'Adda M, Molteni A, Sissa C, Lunghi F, Vismara A, Ubezio M, Guidetti A, Caberlon S, Anghilieri M, Komrokji R, Cattaneo D, Della Porta MG, Giorgino T, Bertù L, Brociner M, Kuykendall A, Passamonti F. Maffioli M, et al. Among authors: carraro mc. Blood Adv. 2022 Mar 22;6(6):1855-1864. doi: 10.1182/bloodadvances.2021006889. Blood Adv. 2022. PMID: 35130339 Free PMC article.
Deferasirox in the management of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study).
Elli EM, Iurlo A, Aroldi A, Caramella M, Malato S, Casartelli E, Maffioli M, Gardellini A, Carraro MC, D'Adda M, Polverelli N, Rossi M, Orofino N, Carrer A, Gambacorti-Passerini C, Antolini L, Passamonti F. Elli EM, et al. Among authors: carraro mc. Br J Haematol. 2019 Sep;186(5):e123-e126. doi: 10.1111/bjh.15964. Epub 2019 May 20. Br J Haematol. 2019. PMID: 31106402 Free article. No abstract available.
15 results